| Short Description : | Recombinant-SARS-CoV-2 Nucleocapsid (B.1.617.2/Delta)-C-His&Avi protein was developed in hek293 cells using the region Ser2-Ala419. For use in research applications. |
| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Formulation: | Supplied as a 0.22 Mu m filtered solution in 20 mM Tris, 150 mM NaCl, 10% Glycerol, pH 8.0. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | <0.1 EU/Mu g |
| Immunogen: | Recombinant SARS-CoV-2 Nucleocapsid (B.1.617.2/Delta) Protein is produced by E. coli expression system. The target protein is expressed with sequence (Ser2-Ala419 (D63G, R203M, D377Y) ) of sars-cov-2 N (B.1.617.2/Delta) (Accession #YP_009724397.2) fu |
| Immunogen Region: | Ser2-Ala419 |
| Immunogen Sequence: | SDNGPQNQRNAPRITFGGPS DSTGSNQNGERSGARSKQRR PQGLPNNTASWFTALTQHGK EGLKFPRGQGVPINTNSSPD DQIGYYRRATRRIRGGDGKM KDLSPRWYFYYLGTGPEAGL PYGANKDGIIWVATEGALNT PKDHIGTRNPANNAAIVLQL PQGTTLPKGFYAEGSRGGSQ ASSRSSSRSRNSSRNSTPGS SMGTSPARMAGNGGDAALAL LLLDRLNQLESKMSGKGQQ |
